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Bacillus anthracis kills through a combination of
bacterial infection and toxemia. Anthrax toxin
working via the CMG2 receptor mediates lethality
late in infection, but its roles early in infection remain
unclear. We generated myeloid-lineage specific
CMG2-deficient mice to examine the roles of macro-
phages, neutrophils, and other myeloid cells in
anthrax pathogenesis. Macrophages and neutrophils
isolated from these mice were resistant to anthrax
toxin. However, the myeloid-specific CMG2-defi-
cient mice remained fully sensitive to both anthrax
lethal and edema toxins, demonstrating that target-
ing of myeloid cells is not responsible for anthrax
toxin-induced lethality. Surprisingly, the myeloid-
specific CMG2-deficient mice were completely resis-
tant to B. anthracis infection. Neutrophil depletion
experiments suggest that B. anthracis relies on
anthrax toxin secretion to evade the scavenging
functions of neutrophils to successfully establish
infection. This work demonstrates that anthrax toxin
uptake through CMG2 and the resulting impairment
of myeloid cells are essential to anthrax infection.
INTRODUCTION
The symptoms of many bacterial diseases are due to the actions
of toxic proteins released by the bacteria. Bacillus anthracis is
such a pathogen, causing anthrax through a combination of
bacterial infection and toxemia (Moayeri and Leppla, 2009).
Anthrax infections are initiated when B. anthracis spores enter
a potential host organism by ingestion, inhalation, or skin abra-
sion. The spores then germinate and replicate as vegetative
bacteria, overcome the host innate immune responses, and ulti-
mately enter the circulation, leading to a systemic infection. In
the bloodstream, B. anthracis multiplies rapidly and secretes
the anthrax toxins, consisting of three components: protective
antigen (PA), lethal factor (LF), and edema factor (EF). PA is
a receptor-binding moiety that generates a protein-conducting
channel for delivering EF and LF into the cytosol to exert theirCell Host &cytotoxic effects. EF, which combines with PA to form edema
toxin (ET), is a calmodulin-dependent adenylate cyclase that
elevates intracellular cAMP levels, thereby mediating diverse
cAMP-induced cellular effects and death of experimental
animals (Firoved et al., 2005; Leppla, 1982). LF, which combines
with PA to form lethal toxin (LT), is a Zn+2-dependent metallopro-
teinase that cleaves and inactivates mitogen-activated protein
kinase kinases (MAPKKs or MEKs) 1–4, 6, and 7 (Duesbery
et al., 1998; Vitale et al., 1998, 2000). This profoundly affects
the many cellular functions that depend on the ERK, p38, and
JNK mitogen-activated protein kinase (MAPK) signaling path-
ways and is sufficient to kill experimental animals (Moayeri
et al., 2003) through mechanisms that are still not well under-
stood. PA binds to two cell surface receptors, tumor endothe-
lium marker-8 (TEM8, also named anthrax toxin receptor 1
[ANTXR1]) and capillary morphogenesis protein-2 (CMG2, also
named anthrax toxin receptor 2 [ANTXR2]) (Bradley et al.,
2001; Scobie et al., 2003). We recently showed that CMG2 is
the major receptor mediating lethality at late stages of anthrax
infection (Liu et al., 2009), but the roles that anthrax toxin and
its cellular receptors play in early stages of infection remain
unclear.
Long beforeMEKswere identified as the specific targets of LF,
it had been found that macrophages from certain mouse strains
are uniquely lysed by LT within 90 min, whereas other mouse
strains have macrophages that are totally resistant to the LT-
induced rapid lysis. This finding directedmuch early work toward
understanding the behavior of this single cell type, which was
suspected of having a key role in pathogenesis (Friedlander,
1986; Friedlander et al., 1993; Moayeri et al., 2004; Moayeri
and Leppla, 2009). The identification of this distinctive pheno-
type, with all mouse and rat macrophages falling into either
‘‘sensitive’’ or ‘‘resistant’’ groups on the basis of their response
to LF, allowed the gene controlling this phenotype to be mapped
to Nlrp1b, for which at least five polymorphic alleles have been
described in both mice and rats (Boyden and Dietrich, 2006;
Newman et al., 2010). However, the LT-induced rapid macro-
phage lysis is not linked in a simple way to anthrax disease,
because mice with ‘‘resistant’’ macrophages can also be killed
by LT, although sometimes with a slower rate than sensitive
mice (Moayeri et al., 2004). In fact, tests of human macrophages
have not shown them to undergo an LT-induced rapid lysis.
‘‘Resistant’’ macrophages are able to bind and internalize LT,
leading to MEK cleavage, and in some circumstances toMicrobe 8, 455–462, November 18, 2010 ª2010 Elsevier Inc. 455
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Figure 1. CMG2-Null Mouse Macrophages Are Completely Resis-
tant to PA + FP59, while Macrophages from TEM8-Null Mice Are
Sensitive
BMDMs from various genotypes as indicated were treated with varying
concentrations of PA in the presence of FP59 (100 ng/ml) for 48 hr. Cell viability
was then evaluated by MTT assay. Data are reported as mean viability ± stan-
dard deviation (SD).
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Anthrax Toxin Targeting of Neutrophils in Anthraxa slow apoptotic death (Park et al., 2002). Paradoxically, mice
with ‘‘resistant’’ macrophages succumb faster than mice with
‘‘sensitive’’ macrophages when infectedwithB. anthracis spores
(Terra et al., 2010; Welkos et al., 1986). For these reasons, it
remains important to determine the contribution that LT targeting
of macrophages plays in pathogenesis in mice, including those
harboring ‘‘resistant’’ macrophages.
Genetics has proven to be a powerful tool for the functional
dissection of toxin-receptor interactions (Liu et al., 2009).
In this study, we generated myeloid-specific CMG2-null mice,
in which both macrophages and neutrophils are unaffected by
anthrax toxin due to lack of its binding and subsequent uptake.
This allowed us to examine the role of macrophages and other
myeloid cells in anthrax toxin pathogenesis, as well as in anthrax
infection. We found that CMG2 is the principal anthrax toxin
receptor on both macrophages and neutrophils. The myeloid-
specific CMG2-null mice retained full sensitivity to both LT and
ET, demonstrating that targeting of macrophages, neutrophils,
and other myeloid cells is not required for the lethality induced
by anthrax toxin. Surprisingly, these myeloid-specific CMG2-
null mice were completely resistant to infection by the toxino-
genic, nonencapsulated B. anthracis Ames strain. It follows
that B. anthracis depends on anthrax toxin to cripple the innate
immune defense function provided by myeloid cells so as to
establish a successful infection.
RESULTS
Generation of Myeloid-Specific CMG2-Null Mice
We previously generated both TEM8 and CMG2-null (TEM8/
and CMG2/) mice by deleting the transmembrane (TM)
domain exons in the TEM8 and CMG2 genomic loci (Liu et al.,
2009). To determine which receptor is preferentially expressed
in mouse macrophages, we analyzed mouse bone marrow-
derived macrophages (BMDMs) from CMG2/ and TEM8/
mice. TEM8/ BMDMs were just as susceptible as C57BL/6
wild-type (WT) BMDMs to PA plus FP59 (Figure 1). FP59 is a
fusion protein of LF amino acids 1–254 and the catalytic domain
of Pseudomonas aeruginosa exotoxin A that kills cells by ADP-
ribosylation and thus inactivation of elongation factor 2 (EF-2)
after delivery to the cytosol by PA (Arora and Leppla, 1993; Liu
and Leppla, 2003b). In contrast, CMG2/ BMDMs were com-
pletely resistant to the toxin (Figure 1), demonstrating that CMG2
is the major anthrax toxin receptor on mouse macrophages.
To explore the role of macrophages in anthrax toxin pathogen-
esis, we generated myeloid-specific CMG2 knockout mice
(CMG2flox/flox/LysM-Cre) in the C57BL/6 genetic background
(Figure 2A). This was achieved by breeding of CMG2flox/flox mice
(having LoxP sites flanking the exon encoding the TM domain of
CMG2) with LysM-Cre targeted mice (having cre recombinase
expression under the control of themyeloid-specific M lysozyme
endogenous promoter), followed by intercrossing of the resulting
CMG2+/flox/LysM-Cremice. The LysM-Cre strain provides a vali-
dated tool for generating mutants in the myeloid cell linage,
including mature macrophages and neutrophils (Clausen et al.,
1999; Mauer et al., 2010). Analysis of the resulting mice by
RT-PCR showed that the CMG2 TM domain was efficiently
deleted in both BMDMs and neutrophils but remained largely
intact in other tissues, including brain, heart, kidney, liver, lung,456 Cell Host & Microbe 8, 455–462, November 18, 2010 ª2010 Elsemuscles, spleen, and thymus, in the CMG2flox/flox/LysM-Cre
mice (Figure 2B). The small amount of the intact allele in neutro-
phils in Figure 2B can be attributed to contamination of the
neutrophil preparation by a small amount of lymphocytes (Fig-
ure S1 available online). The small fraction of the deleted allele
that was observed in other tissues reflects the presence of
myeloid cells residing in these tissues, with a higher fraction in
the lymphoid organs such as the spleen and thymus (Figure 2B).
RT-PCR detected only traces of TEM8 expression in BMDMs
and neutrophils (Figure 2B), indicating that CMG2 is the major
anthrax toxin receptor in both these cell types. As expected,
the BMDMs from CMG2flox/flox/LysM-Cre mice lost the ability to
bind PA, because these cells were highly resistant to PA/FP59,
while BMDMs from WT control mice were sensitive (Figure 2C).
Since primary neutrophils can only survive a few hours in culture,
not allowing a similar cytotoxicity assay, we performed PA/LF
binding and internalization analyses on neutrophils. Neutrophils
of WT mice bound and proteolytically processed PA to the
PA63 heptamer, which was then internalized into endocytic vesi-
cles to form thewell-characterized SDS/heat-resistant heptamer
(Liu and Leppla, 2003a; Liu et al., 2007), resulting in LF delivery to
the cytosol and MEK2 cleavage (Figure 2D). In contrast,
CMG2flox/flox/LysM-Cre neutrophils had much less PA binding
and heptamer formation and no evidence of LF internalization
and MEK2 cleavage (Figure 2D). The trace amounts of PA
binding and heptamer formation may be attributed to the low-
level expression of TEM8 by neutrophils and/or contamination
of lymphocytes during neutrophil isolation. The above results
demonstrate that CMG2 is the major anthrax toxin receptor
expressed on mouse macrophages and neutrophils.Targeting of Mouse Macrophages and Neutrophils Does
Not Contribute to the Lethality Induced by Anthrax Toxin
Since the discovery in 1986 that macrophages from certain
mouse strains are quickly lysed by LT (Friedlander, 1986),
studies of anthrax toxin’s role in vivo have often focused on
this single cell type, in some cases leading to the suggestionvier Inc.
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Figure 2. Generation and Anthrax Toxin Sensitivity of the Myeloid-Specific CMG2-Null Mice
(A) Schematic targeting strategy. Diagram of the CMG2flox allele having exon 12 flanked by LoxP sites (‘‘Floxed’’) and the myeloid-specific CMG2-null allele
(CMG2flox/LysM-Cre). The homozygous myeloid-specific CMG2-null mice (CMG2flox/flox/LysM-Cre) were obtained by the intercrossing of CMG2+/flox/LysM-
Cre mice. The red arrowheads indicate LoxP sites.
(B) RT-PCR analyses of the CMG2 TM domain deletion in various tissues, macrophages, and neutrophils in a CMG2flox/flox/LysM-Cremouse. Macrophages and
neutrophils from a WT mouse were also included as controls. See Figure S1 for neutrophil isolation.
(C) Toxin susceptibility of BMDMs fromWT andmyeloid-specific CMG2-null mice. BMDMswere treated with various concentrations of PA plus FP59 (100 ng/ml)
for 48 hr. Cell viability was evaluated by MTT assay. Data are reported as mean viability ± SD.
(D) Binding and processing of PA onmouse neutrophils. Neutrophils isolated frommouse bone marrow were incubated with 1 mg/ml PA and 0.5 mg/ml LF at 37C
for 0–3 hr. Cells were washed and lysed, and cell lysates were subjected to western blotting with either an anti-PA antiserum or a MEK2 antibody. A nonspecific
cross-reactive band indicated by the arrow head at the lower left of the blot serves as protein loading control.
(E and F) Sensitivity of myeloid-specific CMG2-null mice to the anthrax toxins. CMG2flox/flox/LysM-Cre mice and their control mice were treated with 100 mg PA
plus 100 mg LF (intraperitoneally) (E) or with 50 mg PA plus 50 mg EF (intravenously) (F) and survival monitored for 2 weeks.Whole-bodyCMG2-null mice (CMG2/)
in the same genetic background (C57BL/6) were included as additional controls.
See also Figure S1.
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Anthrax Toxin Targeting of Neutrophils in Anthraxthat release of cytokines from lysing macrophages is the cause
of lethality. To assess the role that anthrax toxin targeting of
mouse macrophages and neutrophils plays in toxin action in
mice, we challenged the myeloid-specific CMG2-null mice with
both LT (100 mg PA + 100 mg LF) and ET (50 mg PA + 50 mg
EF). We found that thesemice were as susceptible asWT control
mice to both LT and ET (Figures 2E and 2F), demonstrating thatCell Host &anthrax toxin-mediated lethality is not due to targeting of macro-
phages and neutrophils.
Myeloid-Specific CMG2-Null Mice Are Resistant
to B. anthracis Infection
We previously showed that CMG2/mice are completely resis-
tant to infection by toxinogenic, nonencapsulated B. anthracisMicrobe 8, 455–462, November 18, 2010 ª2010 Elsevier Inc. 457
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Figure 3. Myeloid-Specific CMG2-Null Mice
Are Resistant to B. anthracis Infection
(A) B. anthracis bacteria are efficiently cleared in
whole-body CMG2-null mice. CMG2/ mice and
their control mice were injected subcutaneously
with 1 3 108 B. anthracis spores. At 8, 24, or
48 hr after the infection, B. anthracis bacteria
were counted in the pooled tissue lysates (which
include heart, lung, kidney, spleen and liver) by
dilution plating on LB agar plates.
(B) Myeloid-specific CMG2-null mice are resistant
toB. anthracis spore infection.CMG2flox/flox/LysM-
Cre mice and their littermate control mice were
subcutaneously injected with 2 3 107 B. anthracis
A35 spores andmonitored for signs of malaise and
survival for 2 weeks. See also Figure S2.
(C) B. anthracis bacteria are efficiently cleared in
myeloid-specific CMG2-null mice. CMG2flox/flox/
LysM-Cre mice and their littermate control
mice were subcutaneously injected with 1 3 108
B. anthracis A35 spores. At 48 hr after infection,
B. anthracis bacteria were counted as described
in (A).
(D) Myeloid-specific CMG2-null mice are resistant
to vegetative B. anthracis A35 infection. Mice were
intravenously injected with 1 3 106 B. anthracis
A35 vegetative bacteria and monitored for survival
for 2 weeks.
(E and F) The anthrax toxins, in particular LT, are
crucial forB. anthracis to overcome innate immune
defense. C57BL/6 mice (WT) were challenged with
1 3 105 (E) or 5 3 106 (F) vegetative B. anthracis
A35 or mutant strains lacking LF (DLF) or EF
(DEF) subcutaneously and monitored for signs
of malaise and survival for 2 weeks. See also
Figure S3.
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Anthrax Toxin Targeting of Neutrophils in AnthraxAmes (A35) spores, while TEM8/mice remain susceptible (Liu
et al., 2009). To further characterize the infectious process, we
compared B. anthracis dissemination in these (whole-body)
CMG2/ and control mice. Bacterial counts in the organs during
the initial 24 hr after subcutaneous B. anthracis A35 spore infec-
tion were low and comparable in both CMG2/ and the WT
control mice (Figure 3A). However, at 48 hr after infection, while
the counts in CMG2/mice remained low, the counts in the WT
control mice were three to four orders of magnitude higher (and
death usually followed a fewhours later in thesemice) (Figure 3A).
These data suggest that B. anthracis bacteria need to overcome
the host innate immune response through targeting CMG2 to
establish a successful infection.
To further explore this hypothesis, we challenged the myeloid-
specific CMG2-null mice with B. anthracis spores. While all their
littermate control mice succumbed to the infection within 6 days,
all CMG2flox/flox/LysM-Cre mice survived infection (Figure 3B).
The B. anthracis bacterial loads in CMG2flox/flox/LysM-Cre mice
were also much lower than those in the WT control mice 48 hr
after infection (103-fold lower than in WT mice, Figure 3C).
Furthermore, B. anthracis bacteria could not be detected in458 Cell Host & Microbe 8, 455–462, November 18, 2010 ª2010 Elsec
B
m
v
o
in
e
a
d
L
g
e
s
u
w
T
a
th
B
tavier Inc.CMG2flox/flox/LysM-Cre mice 2 weeks
after the infection (data not shown). These
results demonstrate that the myeloid-
specific CMG2-null mice are able toompletely clear the B. anthracis infection. In this subcutaneous
. anthracis infection model, after injection of spores in the
ouse upper dorsal area, a subcutaneous edema is usually
isible as early as 8 hr after infection, indicating the occurrence
f spore germination accompanied with anthrax toxin secretion
the local area. The edematous lesion usually progresses to
xtend to the entire upper dorsal area (Figure S2), followed by
systemic infection and death within 6 days after infection. We
id observe this characteristic local edema in CMG2flox/flox/
ysM-Cre mice 1-3 days after infection, indicating that spore
ermination and toxin secretion did occur in these mice. How-
ver, the edema then gradually subsided and mice remained
ymptom-free throughout a 2 week observation period (Fig-
re S2), indicating the failure of the B. anthracis to disseminate
hen the mice contained anthrax toxin-resistant myeloid cells.
hese results demonstrate that B. anthracis uses anthrax toxin
s an essential weapon to target myeloid cells and thereby blunt
e host innate immune response.
To investigate whether themyeloid cell-based defense against
. anthracis infection operates in situations other than the subcu-
neous spore challenge, we also infected mice with vegetative
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A B Figure 4. Depletion of Neutrophils Sensi-
tizes Myeloid-Specific CMG2-Null Mice to
B. anthracis Infection
Mice were depleted of neutrophils by either Ly-6G
1A8 (A) or cyclophosphamide antibody (B) and
then challenged with 5 3 107 B. anthracis A35
spores subcutaneously and monitored for signs
of malaise and mortality for 2 weeks. See also Fig-
ure S4 and Table S1.
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Anthrax Toxin Targeting of Neutrophils in AnthraxB. anthracis A35 bacteria intravenously. Just as in the previous
model, the CMG2flox/flox/LysM-Cre mice were completely resis-
tant to the infection while the WT control mice were sensitive
(Figure 3D). This shows that the host innate immune defense
conferred by myeloid cells is also able to eliminate B. anthracis
vegetative bacteria from the blood stream and organs, as
well as from the subcutaneous tissues infected in the previous
infection model.
LT and ET Are Crucial forB. anthracis to Cause Infection
To explore the roles that LT and ET play in impairing the functions
of innate immunity, we infected WT C57BL/6 mice subcutane-
ously with B. anthracis A35 strains lacking EF or LF (i.e., DEF
andDLF strains). We found that mice survived infections initiated
with either 13 105 or 53 106 A35DLF vegetative bacteria, but all
succumbed to these doses of A35 bacteria (Figures 3E and 3F).
Interestingly, the mice challenged with the A35DLF strain devel-
oped similar degrees of edema as those challenged with the A35
strain during the first 1–2 days after infection, indicating success-
ful initiation of infection by both strains (Figure S3). However, the
edematous lesions caused by the A35DLF strain gradually
subsided within 5 days, whereas the edema in A35-challenged
mice progressed quickly, followed by death within 5 days after
infection. Thus, infections with the A35DLF strain can be
successfully contained, attesting to the importance of LT in
impairing the functions of the myeloid cells so as to facilitate
the infection. The A35DEF was also attenuated in that 90% of
the mice survived infection with 1 3 105 A35DEF bacteria (Fig-
ure 3E). Although the mice did largely succumb (80%) to infec-
tion with 5 3 106 A35DEF bacteria, the mice died at later times
than the A35 treated mice (Figure 3F). These experiments
suggest that EF may also play a role (although a lesser role
than LT) in overcoming the host innate immune response. Edem-
atous lesions did not occur in A35DEF infected mice (Figure S3),
indicating that these lesions resulted from the action of EF.
Taken together, the above results suggest that LF and EF may
coordinate to disable the innate immune functions of themyeloid
cells to facilitate anthrax infections.
Neutrophils Are the Major Cell Type that Control
B. anthracis Infection
During the acute phase of a bacterial infection, the neutrophils
normally located in the blood stream are one of the first types
of inflammatory cells to migrate toward the site of infection.
To determine whether the CMG2-null neutrophils are the majorCell Host &innate immune cells responsible for the resistance of the
CMG2flox/flox/LysM-Cre mice to B. anthracis infection, we
depleted neutrophils from these mice prior to infection. This
was accomplished with either the neutrophil-specific anti-
Ly-6G monoclonal antibody 1A8, which selectively depleted
only neutrophils (Daley et al., 2008) (Figure S4), or with cyclo-
phosphamide, which depleted neutrophils as well as other white
blood cells (Zuluaga et al., 2006) (Table S1). In both cases,
CMG2flox/flox/LysM-Cre mice, which are normally completely
resistant to the infection (as per Figure 3B), became strikingly
sensitized to spore infection, with 80% (five out of six) succumb-
ing to infection when neutrophils were depleted with anti-Ly-6G
antibody and all the mice (six out of six) succumbing when
neutrophils were depleted with cyclophosphamide (Figures 4A
and 4B). Neutrophil depletion also sensitized WT mice to the
infection (Figures 4A and 4B). These results demonstrate that
neutrophils are a major component of the host defenses that
control B. anthracis infections and that B. anthracis production
of LT and ET impairs the neutrophil’s function.DISCUSSION
In the present study, to explore the in vivo role of macrophages
and neutrophils in anthrax pathogenesis, we generated myeloid-
specific CMG2-null mice. We found that CMG2 is the major
receptor for anthrax toxin in both macrophages and neutrophils
because both cell types from myeloid-specific CMG2-null mice
were defective in toxin binding. However, the myeloid-specific
CMG2-null mice remained fully sensitive to both LT and ET, while
whole-body CMG2-null mice were resistant. These results
demonstrate that the lethality caused by anthrax toxin is not
due to targeting of macrophages, neutrophils, or other myeloid
cells.
Macrophages and neutrophils are important components of
host innate immune defenses against bacterial infections (Tour-
nier et al., 2009a). Although these myeloid cells are dispensable
in anthrax toxin-mediated lethality, overcoming host innate
immune defenses provided by themmay be crucial forB. anthra-
cis infections. To test this hypothesis, we infected the myeloid-
specific CMG2-null mice with B. anthracis and compared them
to WT mice. Surprisingly, the myeloid-specific CMG2-null mice
were completely resistant to both the B. anthracis spore and
vegetative bacterium infections while the WT mice were highly
susceptible. In contrast to the WT mice, the myeloid-specific
CMG2-null mice cleared the bacteria. These results reveal thatMicrobe 8, 455–462, November 18, 2010 ª2010 Elsevier Inc. 459
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Anthrax Toxin Targeting of Neutrophils in Anthraxtargeting of myeloid cells by anthrax toxin through the CMG2
receptor is crucial for B. anthracis to establish a successful
infection. We further showed that LT and ET are likely to coordi-
nate to cripple the myeloid cell-mediated innate immune func-
tions, because LF- and EF-deficient B. anthracis mutant strains
had greatly reduced abilities to establish systemic anthrax
infections.
Neutrophils are phagocytes patrolling in blood and represent
the first responders to acute infection. Human neutrophils can
kill B. anthracis spores (Mayer-Scholl et al., 2005). To determine
the roles of neutrophils in early B. anthracis infections, we
depleted neutrophils from both WT mice and myeloid-specific
CMG2-null mice by two different methods prior to infection,
using either cyclophosphamide or the neutrophil-specific anti-
Ly-6G monoclonal antibody 1A8. Remarkably, the myeloid-
specific CMG2-null mice were strikingly sensitized to spore
infection after neutrophil depletion. These results demonstrate
that neutrophils are a major cell type that contributes to control
ofB. anthracis infection, and it is likely the toxin-mediated impair-
ment of their function, acting through the CMG2 receptor, that is
essential for successful infection. The roles of macrophages and
other myeloid cells play in anthrax pathogenesis remains an
open question. Although macrophages are another major cell
type in innate immunity and may play an important role in
controlling anthrax infections, the immune activities of macro-
phages and other myeloid cells appear insufficient to protect
against anthrax infection when neutrophils are depleted.
Anthrax toxin-based vaccines or antitoxin therapies can effi-
ciently protect experimental animals from B. anthracis infection
in various animal models (Tournier et al., 2009b). The results ob-
tained in this study suggest that the protective antibodies
produced in response to vaccination against anthrax toxin may
work at early stages of infections by protecting neutrophils
from LT’s inhibitory action, thus allowing neutrophils to perform
their normal surveillance function in containing infections at an
early stage. It has been argued previously that antibody protec-
tion against many bacterial infections, including those diseases
in which potent secreted toxins play a key role, is achieved at
the earliest stages of an infection by assuring that phagocytes
can destroy the inoculum (Robbins et al., 1995). This principle
may also apply here.
The results presented in this study suggest that the key roles
of anthrax toxin in anthrax infections are those summarized
below: at early stages of infection, B. anthracis spores germinate
locally and secrete LT and ET, which act through binding to
CMG2 receptors and incapacitate myeloid cells (neutrophils
and probably also macrophages). This allows the expanding
population of vegetative cells to evade the powerful antibacterial
functions of myeloid cells. At later stages, after dissemination
and establishment of a systemic infection, B. anthracismultiplies
to high numbers in the blood, producing sufficient amounts of
the anthrax toxins and other virulence factors to kill infected
animals by inducing irreversible damage to nonmyeloid tissues
and cells types. Candidate target cells may include cardiomyo-
cytes and endothelial cells (Moayeri et al., 2009; Warfel et al.,
2005).
This study also provides strong evidence extending the prior
data (Liu et al., 2009) showing that CMG2 is the physiologically
relevant receptor for anthrax infection in vivo.460 Cell Host & Microbe 8, 455–462, November 18, 2010 ª2010 ElseEXPERIMENTAL PROCEDURES
Generation of Myeloid-Specific CMG2-Null Mice
Generation of mice having the CMG2 TM domain exon 12 flanked by loxP sites
(a ‘‘floxed’’ allele), namely, theCMG2flox/floxmice, and their use tomakeCMG2-
null mice (CMG2/) mice were described previously (Liu et al., 2009). For
generation of mice having CMG2 deleted only in the myeloid cell lineage, the
CMG2flox/flox mice were first mated with LysM-Cre targeted mice (Clausen
et al., 1999) (Jackson Laboratories). Myeloid-specific CMG2-null mice
(CMG2flox/flox/LysM-Cre) were obtained by the subsequent intercrossing of
the resulting CMG2+/flox/LysM-Cre mice. Genotyping was performed by PCR
with mouse tail DNA. In analyzing CMG2 expression, total RNA isolated from
various mouse tissues with TRIZOL reagent (Invitrogen, Carlsbad, CA) was
reverse transcribed with the SuperScript III Reverse Transcriptase (Invitrogen).
The 451 bp TM-containing CMG2 complementary DNA (cDNA) fragment was
amplified from WT tissues with a forward and reverse primer pair, 50-GGA
AGAGCAGTCACGTCGATCAGTCA-30 and 50-GACCTCCGTAGTAGGAAGC
GT-30. These primers amplify a 355 bp TM-deleted CMG2 cDNA fragment
from CMG2 TM domain deleted tissues. CMG2-null mice as well as the
myeloid-specific CMG2-null mice were in the C57BL/6 genetic background.
All animal studies were carried out in accordance with protocols approved
by the National Institute of Allergy and Infectious Diseases Animal Care and
Use Committee.
BMDM and Neutrophil Isolation and Cytotoxicity Assay
BMDMs were isolated as described previously (Newman et al., 2010). BMDMs
were cultured in L929 conditioned DMEM with 10% fetal bovine serum (FBS).
Mouse neutrophils were isolated from bone marrow using density gradient
centrifugation with Histopaque 1119 and 1077 according to the manufac-
turer’s manual (Sigma-Aldrich). Neutrophil purity was90%, with a small frac-
tion of lymphocyte contamination (Figure S1). For cytotoxicity assays, BMDMs
were grown in 96-well plates and treated with serial dilutions of PA combined
with 100 ng/ml FP59 for 48 hr. Cell viability was then assayed by MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) as described previ-
ously (Liu and Leppla, 2003a).
PA Binding, LF Translocation, and MEK Cleavage Assays
Neutrophils (13 106) were incubated with 1 ml DMEM with 10% FBS contain-
ing PA plus LF (1 mg/ml and 0.5 mg/ml, respectively) for 0–3 hr at 37C, then
washed five times with Hank’s Balanced Salt Solution (Biofluids, Rockville,
MD) by centrifugation to remove unbound toxins. Cells were then lysed in
modified RIPA lysis buffer containing protease inhibitors (Liu and Leppla,
2003a), and lysates were subjected to SDS-PAGE and western blotting to
detect cell-associated PA and MEK2 cleavage. Anti-PA polyclonal rabbit anti-
serum (#5308) was made in our laboratory. Anti-MEK2 was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA).
B. anthracis Dissemination Experiments
Mice were sacrificed at 8, 24, or 48 hr after subcutaneous infection with
B. anthracis spores (see below). Heart, lung, kidney, spleen, and liver were
pooled and homogenized in PBS, followed by dilution plating of tissue lysates
on LB agar plates.
Toxin and B. anthracis Challenge Studies
In toxin challenge experiments, 8- to 10-week-old male and female mice with
various genotypes were injected with 100 mg PA plus 100 mg LF (in 0.5 ml PBS
intraperitoneally) or with 50 mg PA plus 50 mg EF (in 0.2 ml PBS intravenously)
and observed for signs of malaise twice daily for 2 weeks after injection.
B. anthracis spores were prepared from the nonencapsulated toxinogenic
B. anthracis Ames 35 (A35) strain (Pomerantsev et al., 2006). The EF- or LF-
deficient A35 mutant strains were constructed with a LoxP/Cre-mediated
deletion approach (Pomerantsev et al., 2006). The bacteria were grown on
nutrient sporulation agar at 37C for 3 days, and spores were removed from
plates by washing with sterile water and further purified by centrifugation
(Hu et al., 2006). Spore counts were assessed by dilution plating and micros-
copy. For spore infections, mice were injected with 2 3 107 to 1 3 108 B. an-
thracis A35 spores subcutaneously. For vegetative B. anthracis A35 infection,
mice were injected with 13 105 or 53 106 bacteria subcutaneously or 13 106vier Inc.
Cell Host & Microbe
Anthrax Toxin Targeting of Neutrophils in Anthraxbacteria via tail vein. The challenged mice were monitored twice daily for
2 weeks after infection for signs of malaise or mortality. In neutrophil depletion
studies with cyclophosphamide, mice were injected intraperitoneally with
125 mg/kg of drug 72 and 48 hr prior to infection, and with 200 mg/kg 24 hr
before and 3 hr after infection. For neutrophil depletion with the Ly-6G 1A8
monoclonal antibody (BD PharMingen), mice were injected intraperitoneally
with 100 mg antibody 24 and 6 hr before infection. PA, LF, and EF were purified
as previously described (Liu et al., 2007; Gupta et al., 2008; Firoved et al.,
2005). The LF used here contains the native amino-terminal sequence AGG
(Gupta et al., 2008).
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